Biotech Archives - Page 67 of 795

2 minute read

Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses

April 16, 9:08 AM

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX

2 minute read

AstraZeneca’s Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows

By Vandana Singh

April 16, 8:53 AM

AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival improvement.

AZN

2 minute read

Glucotrack Announces Expansion Of Its Continuous Glucose Monitoring Technology To Epidural Glucose Monitoring

By Benzinga Newsdesk

April 16, 8:47 AM

Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic NeuropathyRutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack,

GCTK

2 minute read

Veracyte Announces 9 Abstracts Reinforcing The Value Of Decipher Prostate And Decipher Bladder Testing Will Be Presented At AUA 2024

By Benzinga Newsdesk

April 16, 8:42 AM

Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual

VCYT

3 minute read

Jaguar Health Licenses FDA-Approved Oral Mucositis Product For U.S. Market, Initiating Commercial Footprint In Its Core Focus Area Of Cancer Supportive Care; Planning To Begin Commercial Launch In Q3 2024 For Gelclair

By Benzinga Newsdesk

April 16, 8:35 AM

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription productOral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology

JAGX

2 minute read

Teva’s New Real-World Evidence Presented At The 2024 AAN Annual Meeting Confirms Effectiveness And Patient Satisfaction For HD Chorea With The 4-week Titration Kit For AUSTEDO Tablets

By Benzinga Newsdesk

April 16, 8:18 AM

Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study resultsSTART study results further support real-world

TEVA

4 minute read

Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting

By Benzinga Newsdesk

April 16, 8:17 AM

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany on track to initiate

ABOS

2 minute read

Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine

By Benzinga Newsdesk

April 16, 8:16 AM

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigerationAmneal plans to launch

AMRX

1 minute read

Monopar Announces Filing Of Patent Protecting MNPR-101 Radiopharma Optimization Findings

By Benzinga Newsdesk

April 16, 8:05 AM

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application

MNPR

2 minute read

Agrify Cannabis Cultivation & Tech Company’s Full-Year Earnings Mark Major Positive Comeback

By Nicolas Jose Rodriguez

April 15, 8:17 PM

Agrify Corporation (NASDAQ: AGFY), a trailblazer in cultivation and extraction technologies for the cannabis sector, has disclosed its financial achievements for the fiscal year ending December 31, 2023, marking a significant turnaround with its first-ever pos

AGFY